公开(公告)号：US10144778B2

公开(公告)日：2018-12-04

申请号：US15125249

申请日：2015-03-12

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/00 ,  A61K31/4155 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/02 ,  A61K39/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US20180327493A1

公开(公告)日：2018-11-15

申请号：US16048422

申请日：2018-07-30

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Idit SHACHAR ,  Inbal BINSKY ,  Ayelet MAROM

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/50 ,  G01N33/574

CPC classification number: C07K16/2806 ,  C07K16/2896 ,  C07K16/3061 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/5011 ,  G01N33/57426 ,  G01N2333/70507 ,  G01N2500/10

Abstract: An isolated antibody comprising an antigen recognition domain which specifically binds CD84 and (i) down regulates the anti-apoptotic activity of stromal cells on chronic lymphocytic leukemia (CLL) cells; and/or (ii) induces mobilization of CLL cells from the bone marrow. Also provided are antibodies comprising antigen recognition domains comprising complementarity determining regions as indicated and uses thereof.

公开(公告)号：US20180327488A1

公开(公告)日：2018-11-15

申请号：US16044636

申请日：2018-07-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Silvia CARVALHO ,  Moshit LINDZEN

IPC: C07K16/22 ,  A61K45/06 ,  A61K31/704 ,  A61K33/24

CPC classification number: C07K16/22 ,  A61K31/704 ,  A61K33/24 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  G01N33/57407 ,  G01N33/57449 ,  G01N2033/57461 ,  G01N2333/485 ,  G01N2333/495 ,  G01N2800/52

Abstract: A method of determining the suitability of a subject to a treatment with an anti-amphiregulin antibody, wherein the subject has a cancer selected from the group consisting of ovarian cancer, head and neck cancer and pancreatic cancer exhibiting resistance to chemotherapy, is provided. The method comprising analyzing in a biological sample of the subject expression level of amphiregulin, transforming growth factor alpha (TGF-alpha) and heparin-binding epidermal growth factor (HB-EGF), wherein a level of expression of the amphiregulin above a predetermined threshold and no expression of the TGF-alpha and/or the HB-EGF or an expression below a predetermined level of the TGF-alpha and/or the HB-EGF is indicative of the suitability of the subject to treatment with the anti-amphiregulin antibody. Methods for treating cancer are also provided, as well as antibodies and pharmaceutical compositions.

公开(公告)号：US20180207247A1

公开(公告)日：2018-07-26

申请号：US15744881

申请日：2016-07-14

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Noga OR-GEVA ,  Eran OPHIR ,  Yaki EIDELSTEIN ,  Rotem GIDRON BUDOVSKY

IPC: A61K39/00 ,  A61K35/17 ,  C12N5/0783

CPC classification number: A61K39/001 ,  A61K35/17 ,  A61K39/39566 ,  A61K2035/122 ,  A61K2039/5158 ,  A61P31/00 ,  A61P35/04 ,  C07K16/2896 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0648 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  Y02A50/467

Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, said anti-third party cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, wherein said cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.

公开(公告)号：US20180207189A1

公开(公告)日：2018-07-26

申请号：US15745441

申请日：2016-07-19

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Steven J.D. KARLISH ,  Adriana KATZ ,  Daniel M. TAL ,  Arie MARCOVICH

IPC: A61K31/7052 ,  A61P27/06 ,  A61P9/00

Abstract: Provided herein are alpha2-selective Na,K-ATPase inhibitors and prodrugs thereof, characterized by having a cyclic moiety attached to a digoxin or digitoxin derivative, as well as uses thereof in lowering intraocular pressure and in treating glaucoma and heart conditions.

公开(公告)号：US20180185477A1

公开(公告)日：2018-07-05

申请号：US15898780

申请日：2018-02-19

Applicant: Yeda Research and Development Co. Ltd. ,  Arizona Board of Regents for and on behalf of Arizona State University

Inventor： Douglas LAKE ,  Benjamin KATCHMAN ,  Deborah FASS

IPC: A61K39/395

CPC classification number: A61K39/3955 ,  A61K38/44 ,  A61K39/39558 ,  A61K2121/00 ,  C07K16/40 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/30 ,  C12Q1/26 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Y108/03002 ,  G01N33/5008 ,  G01N33/5011

Abstract: The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.

公开(公告)号：US10011659B2

公开(公告)日：2018-07-03

申请号：US14956585

申请日：2015-12-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef Yarden ,  Maicol Mancini ,  Nadège Gaborit

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  A61K31/506 ,  A61K31/517 ,  A61K39/395 ,  A61N5/10 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K31/506 ,  A61K31/517 ,  A61K39/39558 ,  A61K2039/507 ,  A61N5/10 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

Abstract: Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.

公开(公告)号：US10000771B2

公开(公告)日：2018-06-19

申请号：US15097340

申请日：2016-04-13

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Rony Seger ,  Dana Chuderland

IPC: A61K38/00 ,  A61K47/00 ,  C12N15/87 ,  C07K14/47 ,  C07K16/28 ,  C07K7/08 ,  C07K16/18 ,  C12N15/113 ,  A61K48/00

CPC classification number: C07K7/08 ,  A61K48/0041 ,  C07K14/47 ,  C07K16/18 ,  C07K16/2866 ,  C07K2319/09 ,  C12N15/113 ,  C12N15/87 ,  C12N2810/85

Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.

公开(公告)号：US20180148770A1

公开(公告)日：2018-05-31

申请号：US15568818

申请日：2016-04-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran ELINAV ,  Eran SEGAL

IPC: C12Q1/689 ,  A61P1/00 ,  A61K31/417 ,  A61K31/132

CPC classification number: C12Q1/689 ,  A61K31/132 ,  A61K31/185 ,  A61K31/417 ,  A61P1/00 ,  G01N33/6893 ,  G01N2800/065 ,  G01N2800/52 ,  A61K2300/00

Abstract: A method of determining the therapeutic effect of an agent, such as a metabolite, comprising: (a) exposing a pathological microbiome to the agent; and (b) comparing the signature of the pathological microbiome following the exposing with a reference signature of a healthy microbiome, wherein when the signature of the microbiome is statistically significantly similar to the healthy microbiome reference signature, it is indicative that the agent has a therapeutic effect on the microbiome. The agent may be provided to a subject having a pathological microbiome once it has been classified as therapeutic.

公开(公告)号：US09982049B2

公开(公告)日：2018-05-29

申请号：US15821603

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: A61K39/395 ,  C07K16/28 ,  A61K38/16 ,  A61K31/4155 ,  A61K45/06 ,  A61K38/18 ,  A61K38/14 ,  A61K38/00 ,  A61K33/36 ,  A61K31/7068 ,  A61K38/20 ,  A61K31/404 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.